Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 3/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 4/20 | 0.35 |
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5103262 | 0.85 | CRHR1 (0.67) | CRHR1 | |
| SCHEMBL5102914 | 0.82 | CRHR1 (0.69) | CRHR1 | |
| SCHEMBL5106141 | 0.80 | CRHR1 (0.88) | CRHR1 | |
| SCHEMBL5103479 | 0.78 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL5771408 | 0.78 | CRHR1 (0.63) | CRHR1CNR2CNR1 | |
| SCHEMBL5099557 | 0.77 | CRHR1 (0.67) | CRHR1MAPT | |
| SCHEMBL5099472 | 0.75 | CRHR1 (0.76) | CRHR1 | |
| SCHEMBL5106053 | 0.73 | CRHR1 (0.87) | CRHR1 | |
| SCHEMBL5098771 | 0.73 | CRHR1 (0.55) | CRHR1 | |
| SCHEMBL5106940 | 0.71 | CRHR1 (0.57) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329667-B2 | A hexahydro-1,5,6,8-tetraaza-acenaphthylene or -1,3,4-triazaphenalene derivatives; treatment of depression and anxiety; inflammatory bowel disease; treatment of conditions mediated by corticotropin-releasing factor | GLAXO GROUP LIMITED (GB) | 2008-02-12 | — | — | US | claimed |
| EP-1383498-B1 | CRF RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2006-03-15 | — | — | EP | claimed |
| US-20040235871-A1 | Crf receptor antagonists | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | US | claimed |
| US-7329667-B2 | A hexahydro-1,5,6,8-tetraaza-acenaphthylene or -1,3,4-triazaphenalene derivatives; treatment of depression and anxiety; inflammatory bowel disease; treatment of conditions mediated by corticotropin-releasing factor | GLAXO GROUP LIMITED (GB) | 2008-02-12 | — | — | US | disclosed |
| EP-1383498-B1 | CRF RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2006-03-15 | — | — | EP | disclosed |
| US-20040235871-A1 | Crf receptor antagonists | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | US | disclosed |
| EP-1383498-A1 | CRF RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002087573-A1 | CRF RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235871-A1 | Crf receptor antagonists | CRHR1, CRHR2, CRH | CRHR1 1/4885SIGMAR1 64/4885CYP3A4 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.